Confidential Technical Documentation
Access Requires a Mutual NDA
The Liver Tissue Digital Twin technical paper contains proprietary simulation architecture, unpublished clinical validation data, and patented methods. Access is available to qualified researchers and pharmaceutical partners under a mutual non-disclosure agreement.
Why an NDA is Required
The digital twin paper documents methods and findings that are the subject of two provisional U.S. patents (App. Nos. 64/100,396 and 64/101,014). It includes unpublished simulation results, proprietary subsystem coupling methodology, and falsifiable predictions that have not yet appeared in peer-reviewed literature. Sharing under NDA protects both parties and preserves the integrity of the patent record.
Patent-Pending Methods
Core simulation architecture and irreversibility prediction algorithms are covered by provisional patents. Unrestricted distribution could affect patent prosecution.
Unpublished Findings
Clinical validation results and falsifiable biomarker predictions are not yet in the public literature. NDA access ensures findings are not disclosed prematurely.
Mutual Protection
The NDA is mutual — Decision Sciences also agrees to protect any confidential information you share during the collaboration discussion.
How to Request Access
Submit the form below
Provide your name, organization, and a brief description of your research interest or intended use.
NDA sent within 48 hours
Wayne Eskridge will review your request and send a mutual NDA for electronic signature via DocuSign or equivalent.
Paper delivered on execution
Upon countersignature, the full technical paper and supplementary data are delivered by secure email.
Request NDA Access
Complete the form below. All fields are required.